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Abstract
COR388,	a	small-molecule	lysine-gingipain	inhibitor,	 is	currently	being	investigated	
in	 a	 Phase	 2/3	 clinical	 trial	 for	 Alzheimer's	 disease	 (AD)	 with	 exploratory	 end-
points	 in	periodontal	disease.	Gingipains	are	produced	by	two	species	of	bacteria,	
Porphyromonas gingivalis and Porphyromonas gulae,	 typically	 associated	 with	 peri-
odontal	disease	and	systemic	 infections	 in	humans	and	dogs,	 respectively.	P. gulae 
infection	 in	dogs	 is	 associated	with	periodontal	 disease,	which	provides	 a	 physio-
logically	relevant	model	to	investigate	the	pharmacology	of	COR388.	In	the	current	
study,	aged	dogs	with	a	natural	oral	infection	of	P. gulae and periodontal disease were 
treated	with	COR388	by	oral	administration	for	up	to	90	days	to	assess	lysine-gingi-
pain target engagement and reduction of bacterial load and downstream pathology. 
In	a	28-day	dose-response	study,	COR388	inhibited	the	lysine-gingipain	target	and	
reduced P. gulae	load	in	saliva,	buccal	cells,	and	gingival	crevicular	fluid.	The	lowest	
effective dose was continued for 90 days and was efficacious in continuous reduc-
tion	of	bacterial	load	and	downstream	periodontal	disease	pathology.	In	a	separate	
histology	study,	dog	brain	tissue	showed	evidence	of	P. gulae	DNA	and	neuronal	ly-
sine-gingipain,	demonstrating	that	P. gulae infection is systemic and spreads beyond 
its	oral	reservoir,	similar	to	recent	observations	of	P. gingivalis	in	humans.	Together,	
the	pharmacokinetics	and	pharmacodynamics	of	COR388	lysine-gingipain	inhibition,	
along with reduction of bacterial load and periodontal disease in naturally occurring 
P. gulae	infection	in	the	dog,	support	the	use	of	COR388	in	targeting	lysine-gingipain	
and eliminating P. gingivalis infection in humans.
K E Y W O R D S
Alzheimer's	disease,	gingipain	inhibitor,	P. gingivalis,	P. gulae,	periodontal	disease
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1  | INTRODUC TION
COR388	is	an	irreversible	active-site	inhibitor	developed	to	target	ly-
sine-gingipain	(Kgp)	in	the	brain	of	Alzheimer's	disease	(AD)	patients.1 
Kgp	is	a	cysteine	protease	virulence	factor	secreted	by	Porphyromonas 
gingivalis,	a	keystone	bacterium	in	the	development	of	periodontal	dis-
ease.2 The secretion of gingipain proteases is part of the asaccharolytic 
metabolism of P. gingivalis, and the gingipains are known to contribute 
to	 dysbiosis,	 immune	 pathway	 induction	 and	 dysregulation,	 chronic	
inflammation,	and	cellular	toxicity.3-7	While	P. gingivalis resides in oral 
biofluids	and	tissues,	 it	has	also	been	shown	to	 translocate	 to	other	
tissues where it is associated with disease pathology including athero-
sclerosis,8	cancer,9	arthritis,10	and	AD.1,11
P. gingivalis is best known for its pathogenic role in periodontal 
disease,	and	periodontal	disease	is	a	risk	factor	for	the	development	
of	 AD,12,13 indicating that a high bacterial load in the oral cavity 
may	be	one	of	many	risk	factors,	along	with	age,	genetics,	bacterial	
strain	virulence,	and	other	variables	that	may	contribute	to	a	chronic	
brain infection with P. gingivalis.	Additionally,	ongoing	moderate	to	
severe periodontal disease has been shown to result in more rapid 
worsening	of	cognitive	decline	in	clinical	AD	patients.14	We	recently	
identified gingipains and P. gingivalis in the brains of subjects with 
AD,	 and	 brain	 gingipain	 levels	 positively	 correlated	 to	 severity	 of	
AD	diagnosis	and	pathology.1	Mechanistic	studies	in	wild-type	mice	
demonstrated that oral infection with P. gingivalis results in brain col-
onization	and	pathology	characteristic	of	AD,1,11 and these effects 
were	blocked	or	reversed	by	COR388.1
As	noted	above,	we	and	others	have	found	that	oral	infection	
of mice with P. gingivalis	 results	 in	translocation	to	the	brain,	 re-
sulting	 in	neurodegeneration	and	AD	pathology,	while	other	oral	
bacteria did not translocate.15	Because	dogs	are	naturally	infected	
with	the	closely	related	species,	P. gulae, and commonly develop 
both periodontal disease16 and canine cognitive dysfunction as-
sociated	 with	 cerebral	 neuropathology,	 including	 amyloidosis,	
tau	 hyperphosphorylation	 and	 neuronal	 loss	 that	 resembles	 AD	
in	humans,17,18	we	aimed	to	examine	the	presence	of	P. gulae and 
associated gingipain proteases in dogs and investigate the phar-
macology	of	the	selective	Kgp	inhibitor	COR388	in	these	animals.	
The	prevalence	of	periodontal	disease	in	dogs	increases	with	age,	
with	40.8%	of	 dogs	1-4	 years	 old,	 and	53.6%	of	 dogs	5-8	 years	
old,	 having	 evidence	 of	 the	 disease,	 with	 prevalence	 increas-
ing	to	>85%	in	dogs	older	than	8	years	of	age.19	 It	was	originally	
thought that P. gulae was the animal biotype of P. gingivalis,	 but	
recent research indicates that P. gulae is also found in humans with 
periodontal	disease,20 and is able to adhere to and invade human 
gingival epithelial cells.21	Importantly,	P. gingivalis and P. gulae are 
the	only	bacterial	species	known	to	produce	gingipains,	which	in-
clude	 the	 arginine-gingipains	 RgpA/B	 in	 addition	 to	 Kgp.22	 Oral	
biofluid	sampling	in	dogs	enabled	us	to	analyze	COR388	Kgp	tar-
get engagement and pharmacologic effects on P. gulae bacterial 
load at multiple time points and doses. These data were used to 
understand	 the	 pharmacology	 of	 COR388	 in	 naturally	 infected	
tissues	 and	 biofluids	 of	 the	 oral	 cavity.	 In	 oral	 tissues,	 systemic	
COR388	treatment	reduced	Kgp	activity	and	P. gulae levels over a 
28-day	period	in	a	dose-dependent	manner.	Based	on	these	data,	
the	lowest	effective	dose	of	COR388	was	chosen	for	administra-
tion	for	90	days,	and	this	dose	demonstrated	efficacy	in	reducing	
periodontal disease pathology.
In	addition,	we	demonstrate	that	P. gulae	DNA	and	Kgp	antigens	
are	present	in	the	aged	dog	brain,	with	similar	histopathology	to	what	
we identified for P. gingivalis	and	gingipains	in	the	human	AD	brain.1 
Thus,	the	preclinical	work	with	COR388	reported	here	allowed	us	to	
pharmacologically	evaluate	the	drug's	ability	to	inhibit	Kgp,	reduce	
P. gulae bacterial burden and disease pathology in a naturally occur-
ring	infection	in	dogs,	providing	proof-of-concept	for	targeting	Kgp	
and P. gingivalis in human studies.
2  | METHODS
2.1 | Dog pharmacology model
Aged	 Beagle	 dogs	 of	 both	 sexes	 ranging	 from	 8	 to	 15	 years	 of	
age,	in	generally	good	health	and	located	in	the	Vivocore	Inc	dog	
colony,	were	utilized	 in	this	study.	All	procedures	were	reviewed	
and	 approved	 by	 Vivocore's	 Institutional	 Animal	 Care	 and	 Use	
Committee	 (IACUC)	and	were	performed	 in	accordance	with	 the	
principles	of	the	Animal	for	Research	Act	of	Ontario	and	the	guide-
lines	of	Canadian	Council	on	Animal	Care	(CCAC).	Structure-based	
design	was	used	to	develop	a	library	of	gingipain	inhibitors,	which	
were	tested	on	purified	Kgp	and	RgpB	to	assess	potency	and	de-
termine inhibition constants. The detailed chemical synthesis and 
structure	of	compounds	in	the	relevant	series	of	 lysine-gingipain	
inhibitors	including	COR388	can	be	found	in	PCT/2016/0061197.	
Detailed	characterization	of	COR388	enzyme	target	binding,	po-
tency,	and	selectivity	are	previously	described.1 Test article admin-
istered,	COR388	HCl,	was	a	solid	powdered	material.	Dogs	were	
dosed	 with	 neat	 compound	 hand-filled	 in	 gelatin	 capsules	 (size	
1,	Torpac)	orally	at	the	 listed	doses	 (free-base,	corrected	for	salt	
form).	All	dogs	utilized	in	studies	were	positive	on	previous	BANA	
enzyme	 (BANAMet	 LLC,	 Ann	 Arbor,	 MI)	 testing	 of	 oral	 plaque	
samples	(assay	described	below).	In	the	first	study,	four	dogs	were	
dosed 10 mg kg−1 q.d. with endpoints assessed after dosing and 
compared	to	those	taken	pre-dose	in	individual	dogs.	The	second	
dose-response	study	was	conducted	with	a	randomized,	blinded,	
matched-group	 design	 with	 12	 dogs.	 Following	 baseline	 sample	
collections	 prior	 to	 dosing,	 animals	 were	 allocated	 to	 four	 dos-
ing	groups,	n	=	3	dogs	per	group	as	follows:	vehicle	 (empty	cap-
sule),	0.15,	0.5,	and	1.5	mg	kg−1	b.i.d	(Q12h).	Dosing	continued	for	
28	days	(0.15	and	1.5	mg	kg−1)	or	90	days	(vehicle	and	0.5	mg	kg−1).	
Groups	were	 balanced	 for	 age,	 sex,	 weight,	 and	 baseline	 BANA	
test	 results	 to	 the	extent	possible.	Dogs	were	group	housed	ac-
cording to dosing group in compliance with the recommendations 
of	the	CACC.	Dogs	were	fed	a	standard	commercial	dry	diet	daily	
in the evenings with water provided ad libitum but not within 
30 minutes of the start of anesthetic procedures.
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Gingival	crevicular	fluid	(GCF),	subgingival	plaque	(SGP),	buccal	
cells,	saliva,	and	plasma	samples	were	collected	and	BANA	enzyme	
testing in the oral cavity was performed throughout the studies. 
Procedures	 for	 oral	 biomarker	 sample	 collection	 are	 described	
below and were performed under general anesthesia induced with 
8	mg	kg−1	of	propofol	(intravenous)	to	effect.	Following	intubation,	
anesthesia	 was	 maintained	 with	 an	 isoflurane-oxygen	 mixture.	
Procedures	 on	 study	Day	 1	were	 performed	 under	 sedation	with	
medetomidine	 (reversed	with	 atipamezole),	 as	 full	 anesthesia	 was	
not required for the collections performed on this day.
For	 evaluation	 of	 pharmacokinetics	 parameters,	 approxi-
mately	2	mL	of	blood	was	collected	at	the	indicated	time	points	
following	 test	 article	 administration	 into	 K2EDTA	 tubes	 and	
plasma was isolated for bioanalytical determination of plasma 
concentrations	of	COR388.	A	single	intravenous	dose	of	COR388	
was	administered	in	PBS	at	a	dose	of	1	mg	kg−1.	Quantitation	of	
COR388	 in	plasma	samples	 following	protein	precipitation	with	
mianserin	added	as	an	internal	standard,	was	performed	from	the	
time	points	shown	using	a	qualified	LC-MS/MS	method	(AB	Sciex	
4000	 QTrap).	 Plasma	 concentration	 versus	 time	 profiles	 were	
analyzed	 to	 determine	 pharmacokinetic	 parameters	 using	 non-
compartmental	 methods	 (Phoenix®	 WinNonlin®	 6.3,	 Pharsight	
Certara).
2.2 | BANA enzyme test
The	 test	 provided	 a	 qualitative	 assessment	 of	 arginine-gingipain	
protease activity derived from oral bacteria by assessing proteo-
lytic	 cleavage	 of	 N-benzoyl-dL-arginine-2-napthylamide	 substrate.	
Subgingival	plaque	was	collected	using	a	dental	scaler	from	the	base	
of	two	teeth	above	the	gum	line.	Plaque	samples	were	applied	to	a	
BANA	test	strip	and	analyzed	with	the	manufacturer's	instructions	
(BANAMet	LLC).
2.3 | Bacterial strains used and growth conditions
P. gingivalis	W83,	P. gingivalis	ATCC	33	277	and	P. gulae	ATCC	51	700	
(ATCC,	 VA)	 bacteria	 were	 grown	 in	 modified	 tryptic	 soy	 broth	
media	 (TSB	media	 supplemented	 with	 5	 mg	mL−1	 yeast	 extract,	
5 μg	mL−1	hemin,	1	μg	mL−1	menadione,	0.5	mg	mL−1	L-cysteine)	to	
late	mid-log	phase,	collected	by	centrifugation	for	20	minutes	at	
4000	g,	washed	 in	PBS,	 then	resuspended	 in	PBS.	Fifty	microlit-
ers	containing	approximately	106	CFUs	bacteria	was	used	for	each	
Kgp	activity	assay,	 for	potency	determination	from	 intact	bacte-
ria.	To	prepare	 lysates	for	analysis,	bacteria	were	washed	 in	PBS	
and	lysed	in	B-Per	lysis	buffer	(Thermo	Fisher	Scientific)	on	ice	for	
20	minutes,	centrifuged	for	30	minutes	at	16	000g,	4°C,	and	su-
pernatant	lysates	collected.	Protein	concentration	was	measured	
using	Pierce	BCA	protein	assay	kit	(Thermo	Fisher).	When	lysates	
were	used	for	Kgp	activity	assays,	500	ng	of	bacterial	lysate	was	
used for the assay.
2.4 | Kgp enzyme inhibition assay
Fifty	microliters	of	each	sample	(intact	bacteria	or	500	ng	bacterial	
lysate)	was	added	to	a	transparent,	black	96	well	plate	and	COR388	
stock	solution	in	PBS	was	added	to	samples	for	final	concentrations	
of	300,	100,	30,	10,	3,	1,	0.3,	and	0	nmol	L−1.	Assay	plates	were	cov-
ered	in	film	with	shaking	for	30	seconds	before	incubation	at	37°C	
for	 30	 minutes.	 Fifty	 microliters	 of	 2X	 protease	 substrate	 Z-His-
Glu-Lys-MCA	(Millipore	Sigma),	to	yield	a	10	μmol	L−1 final concen-
tration	 in	KgP	assay	buffer	 (100	mmol	 L−1	Tris,	 75	mmol	 L−1	NaCl,	
2.5	mmol	L−1 CaCl2,	10	mmol	L
−1	Cys-HCl),	was	added	to	each	sample.	
Enzyme	activity	was	then	immediately	measured	in	a	Synergy	2	mi-
croplate	 reader	 (Biotek)	at	380/460	nm	excitation/emission	wave-
length,	read	every	1.5	minutes	for	30	minutes	with	incubation	and	
shaking	 at	 37°C.	 Enzyme	 activity	 data	were	 analyzed	 using	Gen5	
software	(Biotek).
2.5 | Kgp enzyme inhibition assay in bacterial 
cultures using an activity-based probe
5 × 106	CFU	 in	PBS	were	 incubated	with	COR388	at	 the	concen-
trations	 ranging	 from	 0.3	 to	 1000	 nmol	 L−1	 37°C	 for	 30	minutes,	
followed by the addition of 1 μmol	L−1	COR553	Cy5-labeled	activ-
ity	probe	to	bind	remaining	active	sites	and	 incubated	at	37°C	for	
another	30	minutes.	The	COR553	activity	probe	was	prepared	by	
the	copper-catalyzed	azide-alkyne	cycloaddition	reaction	between	
an	azide	derivative	of	the	irreversible	Kgp	inhibitor	COR553	and	an	
alkyne amide derivative of the Cy5 fluorophore. The probe forms 
an irreversible covalent bond with a catalytic cysteine residue in 
the	 active	 site	 of	Kgp	by	 displacement	 of	 a	 phenol	 leaving	 group,	
and its use has been previously described in detail.1	Sample	loading	
dye	was	added,	samples	heated	at	95°C	for	5	minutes,	and	analyzed	
on	 XT	 Criterion	 gels	 (Biorad).	 Cy5	 probe	 labeled	 protein	 was	 de-
tected	using	a	Chemidoc	imaging	system	(Biorad)	and	quantified	by	
Imagelab	 software	 (Biorad).	A	 rabbit	polyclonal	 anti-Kgp	antibody,	
CAB102,	described	previously,1	was	used	to	detect	Kgp	by	Western	
Blot	analysis	to	ensure	equal	loading	of	bacteria	and	presence	of	the	
enzyme.	This	sample	loading	was	confirmed	in	each	experiment	with	
one	example	included.
2.6 | Oral biofluid sample collection
Saliva:	 Saliva	 was	 collected	 using	 a	 SalivaBio	 collection	 swab	
(Salimetrics	LLC)	on	the	mouth	interior.	The	swab	was	inserted	into	
the	 saliva	 collection	 vial,	 centrifuged	 at	 1500	 g for 15 minutes at 
room temperature. The swab was then removed from the vial and 
the	liquid	sample	was	stored	as	aliquots	of	50-100	μL	at	−80°C	prior	
to analysis.
Subgingival	plaque:	SGP	was	collected	from	eight	different	gin-
gival	 pockets	per	dog	using	Absorbent	Points	 (Coarse,	Premier® 
Dental	Products	Company,	Plymouth	Meeting)	at	times	following	
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dosing	±30	minutes,	as	indicated.	Four	gingival	pockets	were	used	
per	 timepoint.	 Paper	 points	 were	 inserted	 into	 gingival	 pockets	
(held	by	 tweezers)	 until	 resistance	was	 felt	 and	held	 for	30	 sec-
onds.	 Four	 paper	 points	 were	 individually	 washed	 with	 100	 μL	
PBS-0.05%	Tween	for	30	seconds	and	eluate	placed	into	a	1.5	mL	
microcentrifuge	tube.	Eluate	samples	were	stored	at	−80°C	prior	
to analysis.
Gingival	 Crevicular	 Fluid:	GCF	was	 collected	 from	 the	 gingival	
pockets	at	 times	following	dosing	±30	minutes,	as	 indicated.	Eight	
sampling sites were identified per dog and four sites were used per 
timepoint.	 Sampling	 sites	were	 isolated	with	 a	 cotton	 roll	 and	 air-
dried.	 Gingival	 fluid	 collection	 strips	 (Periopaper™,	Oraflow)	were	
gently	held	with	tweezers	and	placed	into	the	pocket	until	resistance	
was	felt.	Strips	were	held	in	place	for	30	seconds	and	then	processed	
as	described	above	for	SGP	isolation.
Buccal	cell:	Four	buccal	swabs	were	performed	on	each	dog	by	
swabbing the inside of the cheek with an oral brush biopsy sampling 
instrument	(OralCDx,	Suffren)	before	dosing	as	well	as	day	14	and	28	
and	for	some	dogs	on	day	48	at	times	following	dosing	±30	minutes,	
as	 indicated.	Two	brushes	were	washed	one	at	a	 time,	 in	a	15	mL	
falcon	tube	containing	1.5	mL	of	DMEM,	solution	transferred	to	a	
1.5	mL	microfuge	tube,	and	centrifuged	at	1500	g for 10 minutes at 
room temperature. Most of the supernatant was aspirated and the 
pellet	was	snap	frozen.	Procedures	were	repeated	for	the	remaining	
two oral brushes.
2.7 | qPCR detection of P. gulae in saliva, buccal 
cells, and GCF
Biofluids	were	evaluated	for	P. gulae	load	using	a	qPCR	assay	that	was	
developed to specifically detect P. gulae	16S	gene	with	the	following	
primers	and	probe:	Forward	primer	CGAGGGGCAGCATGAACTTA,	
Reverse	 primer	 TTGCCCGATCATGCAACCAA,	 and	 probe	
GCGTAACGCGTATGCAACTTGCCTTAC.	 Primers	 were	 designed	
from regions of P. gulae	 16S	 that	have	 sequence	mismatches	with	
P. gingivalis sequence to ensure a specific detection of P. gulae.	Saliva	
was evaluated with either 2 μL	neat	saliva	or	purified	DNA	from	2	μL	
saliva.	Buccal	cells	were	evaluated	with	either	2	μL	neat	buccal	cell	
slurry	or	purified	DNA	from	2	μL	buccal	cell	slurry.	SGP	was	evalu-
ated with 2 μL	from	the	elution	 in	B-Per.	GCF	was	evaluated	with	
either	purified	DNA	from	50	μL	of	B-Per	eluted	GCF	or	neat	2	μL	
elution.
2.8 | Kgp enzyme activity analysis in GCF and SGP 
using an activity-based probe
Twenty	microliters	of	neat	saliva,	SGP	and	GCF	eluates	and	50	μL	
lysed	 buccal	 cell	 slurry	were	 incubated	with	 the	 COR553	 activity	
probe	 as	 described	 above,	 at	 a	 final	 concentration	 of	 1	 μmol	 L−1. 
Probe	binding	analysis	was	performed	as	described	above.	BCA	pro-
tein	detection	assay	results	were	used	to	equally	load	the	gels.	Active	
Kgp	was	extrapolated	from	the	purified	Kgp	(purified	Kgp	was	a	kind	
gift	of	Barbara	Potempa,	University	of	Louisville)	standard	curve	that	
was	run	on	each	gel.	To	normalize	samples	run	on	separate	gels,	the	
extrapolated	Kgp	value	was	divided	by	the	ng	of	total	protein	loaded	
per lane since the value varied between gels.
2.9 | Rgp enzyme activity assay in SGP
For	the	detection	of	arginine-gingipain	 (Rgp)	activity,	cysteine-HCl	
was	freshly	added	to	RgpB	buffer	(100	mmol	L−1	Tris,	200	mmol	L−1 
gly-gly,	5	mmol	L−1 CaCl2)	to	a	final	concentration	of	10	mmol	L
−1 to 
produce	a	RgpB	working	enzyme	assay	buffer.	Purified	RgpB	 (pu-
rified	 RgpB	 was	 a	 kind	 gift	 from	 Barbara	 Potempa,	 University	 of	
Louisville)	was	thawed	on	ice	and	was	added	to	RgpB	working	buffer	
with 2× concentration to prepare standards of final concentration 
from	10	nmol	L−1	to	0.0156	nmol	L−1.	Substrate	L-BapNa	(Sigma)	from	
stock	of	200	mmol	L−1	 in	DMSO	was	added	 to	a	 separate	 tube	of	
RgpB	working	buffer	to	make	concentration	of	2	mmol	L−1 to make 
substrate solution. Ten microliters of dog plaque samples prepared in 
B-per	solution	(Thermofisher)	was	diluted	with	40	μL	of	RgpB	work-
ing solution to be used for the assay. 50 μL	of	2×	enzyme	standards	
and 50 μL	of	sample	solutions	were	added	to	a	pre-cooled	96	well,	
clear	bottom,	black	plate	(Greiner	Bio-One)	on	ice	and	appropriate	
blanks	were	added.	After	50	μL	of	substrate	solution	was	added,	the	
plate	was	 immediately	 read	at	405	nm	 for	1	hour	with	 interval	of	
every	1.5	minutes	 read	 at	 37°C	 and	 continuous	 shaking	 in	Biotek	
Synergy	2	microplate	reader.	COR286,	an	RgpB	inhibitor	previously	
described,1 was used to assess background activity in baseline sam-
ples	and	any	enzyme	activity	seen	not	due	to	RgpB	activity	was	sub-
tracted	 from	 the	 assay.	Detailed	 chemical	 synthesis	 and	 structure	
of compounds in the relevant series of arginine gingipain inhibitors 
including	COR286	can	be	found	in	International	Patent	Application	
PCT/US2015/054050	and	PCT/US2016/061197.
2.10 | Dental assessments
Assessments	were	performed	2	hours	 following	 the	evening	dose	
time	7	days	prior	to	the	start	of	dosing	(predose)	and	also	included	on	
days	27,	28,	29,	91,	and	92.	These	included	an	examination	of	pocket	
depth	 (listed	 in	mm).	Dental	assessments	were	performed	after	all	
biomarker samples were collected so as not to disturb biofluids with 
this assessment.
2.11 | Immunohistochemistry analysis of gingipains 
in dog brain tissue
Immunohistochemistry	(IHC)	staining	was	performed	on	postmortem	
brain	samples	from	four	dogs	not	utilized	in	the	described	pharmacol-
ogy	 studies.	Kgp	was	detected	using	polyclonal	 antibody	generated	
to	a	peptide	from	 lysine-gingipain	CAB102	as	previously	described.1 
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Antibody	specificity	was	confirmed	through	IHC	staining	of	bacteria-
positive	 gingival	 tissues	 and	 pre-absorption	 of	 the	 antibody	 to	 Kgp	
eliminated the brain tissue staining in dog brain tissues.1	Sections	were	
deparaffinized	in	xylenes	and	alcohol	series	and	submitted	to	heat	me-
diated	antigen	 retrieval	 in	citric	acid	at	pH	6.0	 (Vector	Laboratories,	
Burlingame	CA).	Sections	were	blocked	in	5%	normal	horse	serum	with	
0.3%	triton-x-100	 in	PBS	and	 incubated	overnight	at	4°C	 in	primary	
antibody	1:2000	in	2.5%	NHS	and	0.15%	triton-x-100.	After	washing	
three	 times	 in	 PBS,	 Impress	HRP	 polymer	 detection	 kit	 and	 Impact	
DAB	EqV	substrate	were	used	to	visualize	the	primary	antibody	bind-
ing.	 Images	were	 taken	on	an	Olympus	motorized	microscope	BX61	
equipped	with	a	color	CCD	camera	(Olympus,	DP27)	and	processed	for	
brightness	and	contrast	correction,	cropping	and	addition	of	scale	bars	
with	CellSens	1.14	Dimension	software.
2.12 | PCR detection and sequence analysis of 
bacteria in aged dog brain tissue
Frozen	brain	tissue	samples	from	the	same	postmortem	dog	sam-
ples	used	for	 IHC	analysis	of	Kgp	protein	were	also	analyzed	for	
the presence of P. gulae	bacteria	by	qPCR	followed	by	sequence	
analysis	of	the	PCR	product.	qPCR	copy	number	detected	is	shown	
normalized	 per	 brain	 cell	 number	 listed	 knowing	 the	 quantity	
of	 DNA	 utilized	 in	 the	 PCR	 reaction	 and	 average	DNA	 per	 cell.	
Hippocampus	 was	 dissected	 from	 the	 frozen	 brain,	 the	 weight	
measured	and	then	homogenized	in	1	mL	of	ice	cold	RIPA	buffer	
(VWR	Life	Science	RIPA	Lysis	Buffer)	with	the	Qiagen	TissueLyser	
II	at	30	Hz	for	2	minutes.	Protein	lysate	(200	μL)	was	immediately	
transferred	into	1	mL	cold	Trizol	solution	(TRI	reagent,	Millipore).	
After	 removal	of	 the	aqueous	phase	 (standard	TRI	Reagent	RNA	
extraction	protocol,	Millipore),	the	DNA	in	the	phenol	phase	was	
precipitated	with	100%	ethanol,	centrifuged	at	13	500	g,	washed	
again	with	75%	ethanol,	 and	air	dried	 for	10	minutes.	To	ensure	
protein	removal,	the	pellet	was	solubilized	in	ATL	buffer	(Qiagen)	
and	digested	over	night	with	Proteinase	K.	DNA	purification	was	
performed	 according	 to	 the	 instructions	 of	 the	 Qiagen	 DNeasy	
Blood	&amp;	Tissue	Kit.	DNA	was	eluted	from	the	Qiagen	column	
in	 60	mL	 of	 TE	 buffer.	 DNA	 (40	 ng)	 was	 used	 for	 qPCR	 by	 the	
method	described	above	for	biomarker	qPCR	evaluations.
2.13 | Data and statistical analysis
IC50	values	were	extrapolated	using	a	non-linear	fit	for	the	data	plotted	
with	log(conc)	vs	normalized	response	and	the	95%	confidence	interval	
(CI)	 is	 shown	for	each	data	point	 (average	of	N	=	3	 replicates)	using	
GraphPad	Prism	7.	The	normalized	response	for	the	IC50 determina-
tion was performed with respect to no inhibitor control that was set 
to	100%	Kgp	activity.	The	curve	fit	to	the	data	was	evaluated	by	the	
R2	value,	which	was	≥.9	for	all	the	IC50	curves.	All	PK	graphs	(statisti-
cal	significance	 in	GraphPad	Prism	7)	and	parameters	 (statistical	sig-
nificance	 in	WinNonlin)	are	shown	as	mean	with	standard	deviation	
(SD).	All	 target	 engagement	 data	 in	 biomarker	 samples	 is	 presented	
as	the	mean	with	standard	error	of	the	mean	(SEM)	determined	using	
the	Unpaired	t-test	in	GraphPad	Prism	7.	All	values	presented	as	%	of	
baseline	were	calculated	by	setting	the	baseline	to	100%	response	and	
statistical	significance	 is	shown	compared	to	baseline.	Statistical	sig-
nificance where specific groups on a graph were compared is shown by 
bracketed	horizontal	lines.	The	asterisk	convention	to	denote	P value 
was followed: *P < .05; **P < .01; ***P < .001; ****P < .0001.
3  | RESULTS
3.1 | Lysine-gingipains from P. gingivalis and P. gulae 
have similar proteolytic activity
Kgp	 from	 P. gulae and P. gingivalis have similar amino acid se-
quences	and	specific	activity,	 suggesting	similar	 functionality	on	
substrates.22	Using	in	vitro	substrate	cleavage	assays,	we	charac-
terized	the	specific	activity	of	Kgp	from	two	species	of	P. gingivalis 
as well as P. gulae.	 Proteolytic	 activity	 using	 the	 Z-His-Glu-Lys-
MCA	 peptide	 substrate	 was	 assayed	 from	 bacterial	 cultures	 to	
assess	activity	of	bacterial	surface-associated	Kgp	as	well	as	bac-
terial	lysates	in	a	buffer	which	preserves	protease	activity.	Values	
for	 maximal	 velocity	 (Vmax),	 Kgp	 concentration,	 and	 specific	 ac-
tivity	 (rate	 of	 proteolysis)	 were	 similar	 between	 two	 strains	 of	
P. gingivalis and P. gulae	 (Table	1).	These	data	suggest	 that	 these	
Kgp	enzymes	have	similar	 structure	and	specific	activity	and	 in-
dicate	COR388	may	have	potency	across	these	bacterial	species	
and strains.
TA B L E  1   Porphyromonas gingivalis and Porphyromonas gulae	Kgp	proteases	share	similar	gingipain	catalytic	activity
Bacteria
Substrate assay Vmax (min
−1) (107) 
(95% CI)
Substrate assay [Kgp] (nmol L−1) (95% 
CI)
Specific activity (Vmax-
Kgp−1 nmol L−1) (107)
Intact Pg 
(5 × 106 cfu)
Pg lysate 
(500 ng)
Intact Pg 
(5 × 106 cfu) Pg lysate (500 ng)
Intact Pg 
(5 × 106 cfu)
Pg lysate 
(500 ng)
P. gingivalis ATCC	33277 1.67	(1.49-1.88) 2.08	(1.92-2.24) 1.61	(1.31-1.90) 0.80	(0.74-0.85) 1.04 2.6
W83 2.56	(2.16-2.95) 1.45	(1.22-1.69) 1.43	(1.07-1.78) 0.72	(0.58-0.85) 1.79 2.02
P. gulae ATCC	51700 2.08	(1.92-2.24) 1.39	(1.29-1.48) 2.02	(1.61-2.43) 0.88	(0.49-1.27) 1.03 1.58
Note: Protease	activity	in	intact	bacterial	culture	for	the	three	strains	listed	and	separately	from	lysates	prepared	from	these	bacteria	was	measured	
as described in Methods. The specific activity was determined by dividing the protease activity Vmax	with	the	concentration	of	Kgp	identified	in	the	
assays.
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3.2 | COR388 potently inhibits lysine-gingipain 
from both P. gingivalis and P. gulae
The	 inhibition	 of	 Kgp	 protease	 activity	 from	 P. gingivalis by 
COR388	 and	 the	 kinetics	 of	 binding	were	 previously	 reported.1 
In	order	to	confirm	the	potency	of	COR388	on	Kgp	expressed	by	
P. gulae,	 three	 in	 vitro	 assays	were	 conducted.	 Potency	was	 as-
sayed	on	 intact	bacterial	surface-associated	Kgp	(Figure	1A)	and	
on	a	bacterial	 lysate	(Figure	1B).	Potency	of	inhibition	was	single	
digit	nmol	L−1 or lower in both assays and similar between strains. 
Inhibition	of	Kgp	was	 also	 assayed	with	 an	 activity-based	probe	
binding	 assay.	 COR553	 is	 an	 irreversible	 active-site	 Kgp	 probe	
labeled	 with	 Cy5	 for	 detection,	 previously	 described.1	 Bacterial	
cultures	were	 treated	with	COR388	for	30	minutes,	 followed	by	
exposure	 to	 the	COR553	probe	 in	which	 all	Kgp	 active	 sites	 re-
maining	 unbound	 by	 COR388	 are	 bound	 by	 the	 probe.	 Samples	
were	biochemically	separated	and	active	Kgp	detected	with	Cy5	
fluorescence	 and	 total	 Kgp	 protein	 detected	 by	 immunoblotting	
with	CAB102	Kgp-specific	antibody	(Figure	1C	and	D).	IC50 values 
were similar between strains and species and remained single digit 
F I G U R E  1  COR388	has	similar	potency	on	the	Kgp	protease	from	both	Porphyromonas gingivalis and Porphyromonas gulae.	(A)	Bacterial	
surface-associated	Kgp	activity	from	growing	cultures	was	assayed	with	a	substrate	cleavage	assay	(substrate	Z-His-Glu-Lys-MCA)	on	intact	
bacteria;	(B)	Bacterial	lysate	prepared	from	growing	cultures	was	assayed	for	Kgp	activity	with	the	same	substrate	cleavage	assay;	(C	and	D)	
Bacteria-associated	Kgp	activity	was	assayed	from	growing	cultures	using	an	active	site-binding	activity-based	probe	(COR553-Cy5).	Intact	
buffer-washed	bacteria	were	incubated	with	serial	dilutions	of	COR388	for	30	minutes	and	remaining	Kgp	was	detected	by	adding	activity-
based	probe	COR553	for	1	hour	to	bind	remaining	unbound	Kgp.	Proteins	were	separated	biochemically	and	visualized	by	imaging	the	
Cy5	fluorescence,	or	total	Kgp	protein	present	verified	by	immunoblotting	with	CAB102	anti-Kgp	antibody,	with	one	example	immunoblot	
shown	in	C.	The	percent	of	active	Kgp	remaining	(probe	bound)	was	calculated	relative	to	the	maximal	probe	binding	in	the	absence	of	
COR388.	Quantitation	of	C	is	shown	in	D.	IC50	values	in	all	three	assays	were	determined	through	serial	dilutions	of	COR388	and	assessing	
remaining	protease	activity.	Inhibition	constants	are	calculated	as	an	IC50	value	and	the	95%	confidence	intervals	listed	with	each	study	
performed in triplicate
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nmol	L−1	 in	potency.	These	data	confirm	the	potency	of	COR388	
for	the	Kgp	virulence	factor	of	P. gulae.
3.3 | COR388 is orally bioavailable in dogs with 
moderate metabolic stability
Plasma	concentrations	of	COR388	were	measured	after	oral	and	
intravenous	administration	using	LC-MS/MS	methods.	The	phar-
macokinetic	profile	of	oral	doses	of	COR388	administered	in	gela-
tin	capsules	is	depicted	in	Figure	2A	and	after	a	single	intravenous	
dose of 1 mg kg−1	COR388	in	Figure	2B.	Following	intravenous	dos-
ing,	a	moderate	systemic	clearance	(CLS	=	2.1	±	0.6	L	h
−1 kg−1)	and	
large	volume	distribution	(Vss	=	5.2	±	1.3	L	kg
−1)	for	COR388	was	
observed,	 resulting	 in	an	elimination	half-life	of	3.5	±	0.6	hours.	
Excellent	bioavailability	 (%F	=	100%	at	doses	of	0.5	mg	kg−1 and 
higher)	 and	 exposure	 that	 was	 proportional	 to	 dose	 was	 also	
observed for the 0.15 to 10 mg kg−1 oral doses. Mean pharma-
cokinetic parameters for the 0.5 mg kg−1	dose	are	summarized	in	
Figure	2C.	At	this	dose	administered	b.i.d.	for	6	days,	a	Cmax value 
of	66.6	ng	mL−1	was	observed	at	2.17	hours	after	dosing,	with	an	
AUC0-12	h	of	265	h	ng	mL
−1. The mean trough plasma concentra-
tion	 (Cmin)	 value	 12	 hours	 after	 oral	 dosing	 of	 0.5	 mg	 kg
−1 was 
2.67	ng	mL−1.
3.4 | Oral administration of COR388 for 28 days 
results in target engagement and sustained reduction 
in P. gulae bacterial load
Periodontal	disease	mediated	by	pathogenic	bacteria	is	naturally	oc-
curring in dogs and has a similar disease course and microbiology as 
that found in humans.23-25 The natural infection of P. gulae in dogs 
with readily accessible biofluids for bacterial analysis presents an op-
portunity	to	analyze	COR388	pharmacology	and	in	vivo	potency	in	a	
naturally	occurring	infection.	A	colony	of	aged	Beagle	dogs	in	which	
periodontal disease and P. gulae infection was naturally occurring 
was	utilized	to	assess	the	efficacy	of	COR388	in	engaging	the	tar-
get	and	modulating	bacterial	 load.	Target	engagement	of	COR388	
with	the	Kgp	active	site	in	vivo	and	its	effect	on	P. gulae copy num-
ber in oral biofluids was assessed in aged dogs ranging from 10.3 to 
15.4	years	of	age,	following	oral	COR388	administration	at	a	dose	
of 10 mg kg−1	once	a	day	 for	28	days.	Biofluids	assessed	 included	
saliva,	buccal	cells,	subgingival	plaque	(SGP),	and	gingival	crevicular	
fluid	 (GCF).	 Changes	 in	 Kgp	 activity,	 arginine-gingipain	 (RgpB)	 ac-
tivity,	and	P. gulae	bacterial	load	were	measured	from	baseline	pre-
dose	 levels	 in	 individual	dogs.	All	dogs	were	confirmed	positive	at	
baseline	for	periodontal	disease-associated	bacteria	with	a	commer-
cially	available	diagnostic	for	arginine-gingipain	activity	(BANA	test),	
which confirms the presence of a Porphyromonas infection.
Buccal	cells,	known	to	harbor	intracellular	Porphyromonas infec-
tion,	were	assayed	for	P. gulae	bacterial	load	using	qPCR.	Buccal	cells	
were	collected	at	baseline,	day	14,	and	day	28	of	dosing.	Dosing	was	
stopped	on	day	29,	followed	by	a	period	with	no	dose	administration	
(to	day	44).	A	mean	decrease	of	>	80%	in	baseline	P. gulae	DNA	was	
observed	in	buccal	cells	after	14	days	of	dosing,	dropping	further	on	
day	28	(Figure	3A).	A	small	recovery	of	bacterial	load	was	observed	
on	day	44	(Figure	3A)	indicating	a	durable	response	in	reducing	the	
bacteria,	but	also	a	slow	recovery	due	to	either	reinfection	or	pro-
liferation of remaining bacteria. These data support the need for 
chronic dosing to achieve sustained reduction of P. gulae and for the 
potential	of	therapeutic	efficacy.	Saliva	samples	were	also	assayed	
for P. gulae	 load	using	qPCR	after	14	and	28	days	of	dosing.	While	
the level of the bacterial load in saliva was more variable than that 
observed	in	buccal	cells,	a	similar	reduction	from	baseline	levels	was	
observed	after	28	days	of	COR388	administration	(Figure	3B).
GCF	collected	on	and	eluted	from	paper	strips	was	also	assayed	
for P. gulae	DNA	by	qPCR	and	Kgp	activity	using	the	activity-based	
active	site	probe	COR553.	Kgp	activity	was	robustly	detected	with	
this	method,	consistent	with	the	presence	of	the	bacteria.	COR553	
probe-bound	Kgp	was	present	at	baseline	predose	on	day	1	and	re-
duced	in	samples	taken	2	hours	after	dosing	on	day	14	and	day	28	
(Figure	3C).	These	data	indicate	the	presence	of	active	Kgp	available	
for probe binding in all dogs on day 1 and indicate that no active sites 
F I G U R E  2  COR388	pharmacokinetic	(PK)	profile	and	parameters	with	oral	and	intravenous	administration.	(A)	Plasma	PK	profile	of	listed	
single	oral	doses	(10,	1.5,	0.5,	and	0.15	mg	kg−1)	administered	in	gelatin	capsules.	(B)	Plasma	PK	profile	of	single	intravenous	administration	
(1	mg	kg−1)	administered	in	phosphate	buffered	saline.	(C)	PK	parameters	following	a	single	oral	dose	were	calculated	using	WinNonlin	
and are shown where Tmax	is	the	time	to	achieve	maximal	plasma	concentration;	Cmax	is	the	maximal	concentration	achieved;	Apparent	t1/2 
is	the	time	to	reduce	maximal	concentration	by	half;	AUC0-12h is the area under the curve for 12 hours after administration; and F is the 
bioavailability assessing the fraction of the drug reaching systemic circulation
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were	available	for	probe	binding	on	days	14	and	28.	Quantitation	of	
the	Kgp	protein	was	performed	using	reference	standards	of	purified	
Kgp	also	bound	to	the	active	site	probe.	The	level	of	reduction	in	ac-
tive	Kgp	from	baseline	is	quantified	in	Figure	3D.	Reduced	levels	of	
the	total	Kgp	protein,	detected	with	a	polyclonal	anti-Kgp	CAB102	
antibody,	were	seen	in	these	same	lysates	following	COR388	admin-
istration	on	days	14	and	particularly	on	day	28,	suggesting	that	the	
Kgp	protein	 in	total	was	reduced.	There	 is	no	 loading	standard	for	
GCF	and	therefore	relative	comparisons	to	untreated	samples	were	
performed. This reduction is consistent with the results of reduced 
P. gulae bacterial burden observed in buccal cells and saliva and is 
consistent	with	 the	 inhibition	of	Kgp	and	subsequent	clearance	of	
the P. gulae	infection	following	administration	of	COR388.
SGP	was	also	collected	and	assayed	for	P. gulae	DNA	by	qPCR	
and	Kgp	 activity	 using	 the	 COR553	 probe.	 Kgp	 activity	 is	 signifi-
cantly	 reduced	with	COR388	administration	 similar	 to	 the	data	 in	
GCF	 (Figure	 3C).	 In	 addition,	 RgpB	 protease	 activity	was	 assayed	
using	 a	 substrate	 cleavage	assay	 in	 SGP	as	described	 in	Methods.	
Active	RgpB	was	detected	at	baseline	on	day	1	with	a	reduction	fol-
lowing	COR388	administration	 (Figure	3E).	This	 is	 consistent	with	
the reduction in P. gulae	levels	also	observed,	as	levels	of	all	bacteri-
al-produced	proteins	would	likewise	be	expected	to	fall	concurrent	
with a reduction in bacteria.
Together these data on multiple readouts of gingipain activity 
and P. gulae	load,	from	independent	oral	biofluids	harboring	the	bac-
teria,	are	consistent	with	COR388	target	engagement	on	Kgp	and	
subsequent reduction in bacterial burden.
3.5 | Oral administration of COR388 results in dose-
dependent Kgp target engagement
Kgp	active	site	inhibition	as	well	as	a	robust	anti-bacterial	response	
was	observed	 in	 the	 first	study.	A	second	study	 in	an	 independent	
cohort	of	aged	dogs	was	performed	to	assess	the	dose-response	re-
lationship	of	COR388	including	a	vehicle	control.	In	this	second	study,	
12	aged	dogs	8.6-14.6	years	of	age,	identified	as	BANA-test	positive,	
were	randomized	into	four	study	groups	balanced	for	age,	sex,	weight	
and	baseline	BANA	results.	Dogs	were	dosed	with	COR388	in	cap-
sules	 including	a	 vehicle	 group	 (empty	 capsule)	with	0.15,	0.5,	 and	
1.5 mg kg−1	b.i.d.	dose	groups.	Having	demonstrated	 similar	 target	
engagement and reduction of P. gulae	DNA	in	multiple	biofluids	in	the	
first	study,	biomarker	analysis	in	this	second	study	was	focused	on	a	
subset	of	biomarkers	and	biofluids	to	be	able	to	analyze	more	time	
points	as	well	as	periodontal	disease	endpoints.	In	this	study	GCF	was	
analyzed	for	detection	of	Kgp	activity	and	buccal	cells	were	analyzed	
for P. gulae	DNA	quantitation.	DNA	purification	and	normalization	to	
GAPDH	DNA	was	added	to	the	buccal	cell	analysis	for	normalization	
and	quantitation	of	bacterial	copy	number.	GCF	and	buccal	samples	
were collected as described in Methods and biomarkers evaluated 
in	all	dogs	prior	to	dosing,	multiple	times	after	the	first	dose,	and	at	
single	time	points	on	days	14	and	28	of	the	study.	Collection	12	hours	
after the first dose was included to assess biomarker activity at the 
plasma	pharmacokinetic	trough	concentration	(Cmin).
Kgp	activity	in	GCF	was	again	assessed	using	the	COR553	probe.	
Early	time	points	allow	assessment	of	target	engagement	 in	which	
F I G U R E  3  COR388	oral	administration	at	a	dose	of	10	mg	kg−1 results in sustained decrease in gingipain activity and bacterial burden. 
(A)	Dogs	were	dosed	from	day	1	to	day	28;	sample	was	taken	16	days	following	cessation	of	dosing	on	day	44.	(B)	P. gulae copy number 
from	2	mL	saliva	normalized	to	predose.	(C)	Kgp	activity	was	assayed	in	GCF	and	SGP	using	activity-based	COR553	probe	as	described	
in	Methods.	Kgp	protein	was	assayed	by	a	Western	blot	using	the	polyclonal	CAB102	antibody.	Purified	Kgp	and	P. gingivalis	W83	lysates	
were	run	as	positive	controls.	(D)	Levels	of	Kgp	activity	normalized	to	individual	predose	values	were	quantified	from	C.	(E)	RgpB	substrate	
cleavage	assay	in	SGP	samples,	with	values	normalized	to	predose	levels.	Significance	was	determined	using	a	t-test	and	mean	±	SEM	values	
are shown
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the	bacteria	and	Kgp	protein	are	not	yet	cleared.	As	expected,	strong	
probe	binding	was	detected	in	baseline	samples.	Kgp	activity	was	in-
hibited	by	COR388	in	a	dose-dependent	manner	(Figure	4;	Figure	S1)	
indicating	active	site	target	engagement	by	COR388.	Kgp	inhibition	
increased	between	2	and	12	hours	after	the	first	dose	and	was	maxi-
mal	at	the	highest	dose	administered	(Figure	4A-C).	Furthermore,	the	
F I G U R E  4  COR388	inhibits	Kgp	in	a	
dose	and	time	dependent	manner.	(A-C)	
Target	engagement	at	0	(predose),	2	and	
12 hours after the first dose on day 1 was 
measured	using	COR553	probe	binding	
and quantitated by densitometry to 
measure inhibition in all dosing groups. 
Fluorescent	probe	images	from	Figure	
S1	were	quantitated	and	ng	of	Kgp	was	
determined	by	the	purified	Kgp	standard	
curve.	Percent	inhibition	from	baseline	
(normalized	to	0%	inhibition)	is	shown,	
plotting	mean	±	SEM.	(D)	The	time	course	
of	this	target	engagement	in	GCF	(percent	
inhibition	from	baseline)	for	all	doses,	is	
shown	on	days	1,	14,	and	28
F I G U R E  5  COR388	administered	0.5	mg	kg−1	b.i.d.	resulted	in	pharmacologic	efficacy	in	periodontal	disease.	(A)	P. gulae copy number 
using	16S	primers	in	DNA	isolated	from	buccal	cells	at	baseline	on	day	1	and	day	90	is	shown,	normalized	to	cellular	GAPDH	DNA	levels.	(B)	
Normalized	Kgp	activity	(ng)	in	GCF	at	baseline	on	day	1	and	on	day	90	is	shown.	The	method	for	normalization	is	described	in	the	methods	
section.	(C)	Change	in	average	pocket	depth	from	baseline	on	day	90	is	shown	where	each	dot	represents	the	numerical	change	(mm)	from	
baseline	measured	for	each	dog.	Negative	change	in	pocket	depth	indicates	improvement.	(D)	Waterfall	plot	for	change	in	individual	pocket	
depths	for	all	pockets	in	vehicle	and	COR388	groups	that	were	either	a	pocket	depth	of	3	mm	or	greater	at	baseline	or	day	90.	Equal	number	
of	pockets	were	assayed	for	COR388	and	vehicle	groups.	(E)	All	pockets	in	vehicle	and	COR388	groups	that	were	either	a	pocket	depth	of	
3 mm or greater at baseline or day 90 were averaged for each dog and that average per dog was plotted and grouped in either a vehicle or 
COR388	group	for	graphing.	This	graph	is	a	subset	analysis	of	graph	C	and	the	data	points	used	are	individually	plotted	in	graph	D.	Statistical	
significance shown based on standard t-test	using	Graphpad	PRISM,	with	plots	showing	mean	±	SEM
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level	of	Kgp	 inhibition	 increased	with	repeated	dosing	for	28	days	
resulting	in	a	greater	level	of	inhibition	over	time	(Figure	4D),	likely	
also reflecting a reduction in P. gulae	and	Kgp	levels.	These	studies	
demonstrated	a	dose-dependent	decrease	 in	Kgp	activity	2	hours	
post	dose	(near	the	plasma	Tmax	exposure)	with	negligible	recovery	
of activity indicating continued target engagement and inhibition 
for	 12	 hours	 following	 the	 dose	 (at	Cmin)	 (Figure	 4A-C	 and	 Figure	
S1B-E).	While	variable	between	dogs,	inhibition	at	all	doses	generally	
increased	with	increasing	time	of	exposure	on	day	1	(Figure	S1F-H).	
It	was	noted	that	one	dog	receiving	a	dose	of	0.15	mg	kg−1 had min-
imal	Kgp	inhibition	on	all	days	and	this	dog	had	the	lowest	exposure	
of all dogs with a plasma Cmax	of	only	2.73	ng	mL
−1 compared with 
the mean Cmax	of	9.74g	mL
−1	 in	 that	dose	group,	consistent	with	a	
dose-response	 relationship	 of	 Kgp	 inhibition.	While	 some	 natural	
variability	 in	Kgp	activity	can	be	seen	over	 time,	 inhibition	of	Kgp	
activity	in	GCF	was	not	detected	in	the	vehicle-treated	dogs	(Figure	
S1A	and	E).	These	data	support	dose-dependent	inhibition	of	Kgp	in	
oral	biofluids	following	administration	of	COR388.
3.6 | Extended dosing of COR388 for 90 days is 
efficacious in reducing pocket depth in dogs
Having	established	target	engagement	and	 inhibition	 in	a	dose-de-
pendent	manner,	one	dose	was	chosen	to	continue	for	90	days	to	de-
termine	if	extended	dosing	would	result	in	a	prolonged	reduction	of	
P. gulae bacterial burden and efficacy in reducing periodontal disease 
pathology.	 Pocket	 depth,	 a	 measure	 of	 gingival	 inflammation	 and	
clinical	 attachment	 loss	 (CAL)	 associated	with	periodontal	 disease,	
was assessed in the dogs prior to the start of dosing and measured 
after	90	days	of	administration.	Near-complete	Kgp	inhibition	in	all	
three	dogs	was	detected	over	28	days	using	 the	0.5	mg	kg−1 dose 
and	therefore,	this	dose	was	extended	along	with	the	vehicle	control	
group	for	this	90-day	study.	COR388	plasma	exposure	for	this	dose	
was	similar	to	that	seen	with	a	maximally	efficacious	dose	in	a	mouse	
model of P. gingivalis infection.1	 Monitoring	 of	 Kgp	 activity	 and	
P. gulae	in	GCF	samples	was	continued	in	these	dose	groups.	COR388	
administration resulted in statistically significant reduction in P. gulae 
bacterial	 load	over	 time	as	well	as	Kgp	activity	when	compared	to	
the	vehicle	control	animals	(Figure	5A	and	B).	The	data	suggest	that	
continued	COR388	administration	kept	bacterial	burden	reduced	in	
contrast to the rise in P. guale load in the vehicle dosed group.
Gingival	pocket	depths	were	measured	from	10	teeth	from	three	
pockets	(Rostral,	Lateral,	and	Caudal)	on	each	tooth.	Pocket	depths	
were	 reduced	with	 COR388	 administration,	 indicative	 of	 reduced	
periodontal	 disease	 and	 associated	 inflammation.	 In	 contrast,	 the	
vehicle dosed group progressed with increases in pocket depth. 
There	was	a	reduction	in	mean	average	pocket	depth	with	COR388	
administration when changes in all individual pocket depths were 
measured	(P	=	.0156)	(Figure	5C).	Pocket	depths	in	this	model	≥3	mm	
are	consistent	with	periodontal	disease	pathology.	A	waterfall	plot	
of	 the	 change	 in	 pocket	 depth	 size	 from	 day	 1	 to	 day	 90,	 for	 all	
pockets	≥3	mm	at	baseline	or	on	day	90,	 illustrated	that	the	pock-
ets	that	decreased	were	primarily	in	animals	administered	COR388	
(Figure	5D).	A	significant	 reduction	 in	mean	average	pocket	depth	
≥3	mm	 at	 baseline	 or	 end	 of	 study	 per	 dog	with	 COR388	 dosing	
was	seen	when	this	subset	of	most-effected	pockets	was	analyzed	
(P	=	.0332)	(Figure	5E).	By	contrast,	pocket	depth	tended	to	increase	
in dogs receiving the vehicle control.
3.7 | Detection of Kgp antigens and identification of 
P. gulae 16S rRNA gene in aged dog brains
Lastly,	 we	 were	 interested	 in	 determining	 if	 P. gulae shared the 
same property of systemic translocation as P. gingivalis,8,26,27 es-
pecially	to	the	brain,1 because if such an infection is present in the 
dog,	the	dog	could	become	an	important	animal	model	for	future	
COR388	 studies	 in	 treating	P. gulae/gingipain translocation from 
the oral cavity to the brain. To determine if dog brains are infected 
F I G U R E  6  Detection	of	Kgp	antigens	and	P. gulae	DNA	in	aged	dog	hippocampal	samples.	(A)	Kgp	IHC	with	polyclonal	antibody	CAB102	
on	dentate	gyrus	granule	cells	and	cornus	ammonis	(CA)	pyramidal	neurons	of	the	hippocampus.	Representative	images	of	Kgp	staining:	dog	
A	5.2-yo,	dog	B	8.6-yo,	dog	C	8.6-yo,	dog	D	14.9-yo.	Scale	bars	200	μm.	(B)	qPCR	detection	of	P. gulae	16S	DNA	in	frozen	hippocampal	tissue	
samples	from	the	dogs	shown	in	A.	(C)	Sequence	analysis	of	the	PCR	product	from	dog	D	was	performed	and	analyzed	against	the	P. gulae 
sequence	database	(NCBI)
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with P. gulae,	postmortem	brain	tissue	sections	from	the	hippocam-
pus	of	4	dogs	 that	were	not	part	of	 the	current	COR388	PK/PD	
study	reported	here	were	stained	for	the	presence	of	Kgp	protein	
by	IHC	using	a	Kgp	specific	antibody.	Kgp	staining	was	detected	in	
the	hippocampus	 in	the	three	older	dogs	 (aged	8-14	years),	most	
prominently	in	pyramidal	neurons	in	the	cornu	ammonis	(CA),	while	
little	 to	 no	 staining	 was	 seen	 in	 the	 5-year-old	 dog	 (Figure	 6A).	
Next,	 frozen	 hippocampal	 tissue	 samples	 from	 these	 same	 dogs	
were	assessed	by	qPCR,	with	the	results	confirming	the	presence	
of P. gulae	DNA	(Figure	6B).	Sequence	analysis	of	the	PCR	product	
confirmed	the	identity	of	the	qPCR	product	as	P. gulae	(Figure	6C).	
These results are consistent with a systemic infection of P. gulae in 
aged dogs and are concordant with the ability of this bacterium to 
translocate	from	the	oral	cavity	and	colonize	other	tissues	includ-
ing the brain.
4  | DISCUSSION AND CONCLUSIONS
The results reported here support identification of a dose of 
COR388	necessary	 for	 inhibition	 of	 the	 gingipain	 virulence	 factor	
Kgp	and	the	reduction	of	a	naturally	occurring	oral	P. gulae infection 
in dogs. These findings are consistent with our prior study demon-
strating	 that	 targeting	 Kgp	with	 COR388	 decreased	 the	 bacterial	
load of P. gingivalis	 and	AD	 related	disease	pathology	 in	 the	brain	
of	 wild-type	 mice	 orally	 infected	 with	 P. gingivalis.1	 Importantly,	
we	demonstrate	here	that	Kgp	proteases	derived	from	P. gulae and 
P. gingivalis	 have	 similar	 proteolytic	 activity	 and	 that	COR388	 is	 a	
potent	irreversible	inhibitor	of	both	proteases.	Therefore,	COR388	
is predicted to have efficacy in diseases in which one or both of 
these bacterial pathogens are causative agents for disease pathol-
ogy.	In	the	pharmacokinetics	and	pharmacodynamics	studies	in	the	
dog,	COR388	was	shown	to	be	orally	bioavailable	and	demonstrated	
dose-	and	time-dependent	Kgp	active-site	target	engagement,	with	
good	tissue	distribution	as	evidenced	by	Kgp	inhibition	in	both	sub-
gingival plaque and gingival crevicular fluid. These data also demon-
strated that target engagement was sustained beyond peak plasma 
exposure,	consistent	with	irreversible	target	binding.	In	addition	to	
this	 long-lasting	 nature	 of	 pharmacodynamic	 engagement	 on	 the	
target,	Kgp	inhibition	at	lower	doses	increased	to	that	observed	by	
a	higher	dose	 following	prolonged	administration.	 Specifically,	 the	
0.5 mg kg−1	dose	provided	roughly	50%	 inhibition	of	baseline	Kgp	
activity	after	a	single	dose	but	near	complete	inhibition	after	28	days	
of	dosing	(Figure	4D).	Re-emergence	of	a	low	level	of	infection	after	
16	 days	 following	 cessation	 of	 dose	 administration	 (Figure	 3A)	 is	
consistent with the need for chronic repeated administration to sup-
press bacterial survival and replication. This sustained target inhibi-
tion decreased P. gulae load and downstream periodontal pathology 
with	 prolonged	 dosing.	 Lastly,	 we	 found	 evidence	 of	P. gulae and 
neuronal	Kgp	in	dog	brains,	similar	to	results	recently	published	for	
P. gingivalis	and	Kgp	in	human	AD	brains.1
The focus of the current studies was to understand the phar-
macokinetics	and	pharmacodynamic	target	engagement	of	COR388	
in	aged	dogs,	as	such	we	did	not	power	the	study	for	cognitive	ef-
fects of the test article which would have required a larger num-
ber	of	dogs,	potentially	 a	 longer	period	of	 continuous	dosing,	 and	
was	outside	of	the	scope	of	this	study.	Cognitive	effects	of	COR388	
administration,	as	well	as	changes	in	inflammatory	and	periodontal	
disease	markers,	are	currently	being	studied	in	a	large	international	
trial	of	patients	with	mild-to-moderate	AD	(GAIN:	ClinicalTrials.gov,	
NCT03823404).
We	 suggest	 that	 infection	 of	 the	 oral	 cavity	 is	 the	most	 likely	
source of P. gingivalis or P. gulae and associated gingipains translo-
cating to the brain and other organs in humans and dogs. The study 
reported here demonstrated that the small molecule gingipain inhib-
itor,	COR388,	has	distribution	to	the	oral	cavity	and	oral	biofluids,	
which	contain	a	high	bacterial	burden,	in	sufficient	concentrations	to	
penetrate	oral	biofilms,	engage	the	gingipain	target,	and	reduce	the	
oral	bacterial	load.	The	consistent	reduction	in	Kgp	activity	coupled	
with	the	downstream	reductions	in	bacterial	load	and	RgpB	activity	
in	multiple	independently	isolated	oral	biofluids,	as	well	as	the	buccal	
epithelial	cells	known	to	harbor	intracellular	infection,	is	evidence	of	
broad	systemic	targeting	of	this	pathogen	by	COR388.	Specifically,	
the doses used in this study illustrate the therapeutic efficacy of 
COR388	 in	reducing	a	preexisting,	established	natural	 infection	of	
the bacteria.
Because	 Kgp	 can	 be	 produced	 by	 both	 P. gingivalis as well as 
P. gulae,	 the	target	engagement	of	Kgp	demonstrated	here	will	 re-
flect inhibition of the protease target in both species if both are 
present	in	the	dogs.	As	we	had	previously	demonstrated	the	efficacy	
of	COR388	on	Kgp	and	P. gingivalis bacterial infection in a mouse 
model,	we	 chose	 to	monitor	P. gulae bacterial load in the current 
study	to	confirm	that	COR388	could	also	reduce	the	load	of	P. gulae 
in vivo.
Our	previous	study	in	mice	demonstrated	that	COR388	is	brain	
penetrant and efficacious in reducing established brain P. gingivalis 
load	and	AD	pathology.1	This	ability	of	COR388	to	effectively	inhibit	
gingipain with broad tissue distribution should promote the clear-
ance of gingipains and P. gingivalis/P. gulae from multiple reservoirs in 
the	body.	We	previously	demonstrated	that	chronic	administration	
of	COR388	to	P. gingivalis cultures in vitro did not lead to drug resis-
tance,1 and no loss of bacterial suppression was seen in the current 
study	when	COR388	was	administered	continuously	over	a	period	
of 90 days.
In	conclusion,	the	Kgp	active	site	is	conserved	between	P. gingi-
valis and P. gulae,	and	COR388	shows	potent	inhibition	of	Kgp	orig-
inating	 from	both	 bacterial	 species.	 In	 the	 dog,	 systemic	COR388	
gained	access	to	Kgp	within	oral	biofilms	that	are	normally	difficult	
to	 penetrate,	 and	 Kgp	 target	 engagement	 reduced	 P. gulae load 
and	downstream	pathology,	 including	decreased	 inflammation	and	
periodontal	disease.	Since	there	 is	emerging	evidence	that	P. gulae 
infects	humans,20 and could potentially contribute to the infection 
in	AD	patients,	 it	was	 important	 to	demonstrate	 in	 this	study	that	
COR388	inhibits	the	critical	virulence	factor	Kgp	from	both	P. gulae 
and P. gingivalis,	supporting	ongoing	use	of	COR388	to	treat	these	
infections in human clinical studies.
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